Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Cardiologist and Men's Health advisory board member Christopher Kelly, MD, says this treatment is "approaching magic" for ...

A new paper from the University of Kansas overturns the idea that a "risk gene" carried by millions of people worldwide ...

Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an ...

Exa-cel is the first FDA-approved therapy utilizing CRISPR/Cas9, a type of gene editing technology through which patients' ...

This radical new method could preserve our entire knowledge base for thousands of years, in a storage medium the size of a coffee cup.

CRISPR screens often mislead cancer research because bacterial Cas9 components trigger immune reactions in mice. ETH Zurich researchers developed a “stealth” CRISPR approach that removes immunogenic ...

TriLink BioTechnologies senior scientist Dr Cody Palumbo discusses the blockers to manufacturing mRNA-based gene editing ...

JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing ...